Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Novel Synthetic Oxazines Target NF-κB in Colon Cancer In Vitro and Inflammatory Bowel Disease In Vivo

  • Anilkumar C. Nirvanappa,
  • Chakrabhavi Dhananjaya Mohan,
  • Shobith Rangappa,
  • Hanumappa Ananda,
  • Alexey Yu Sukhorukov,
  • Muthu K. Shanmugam,
  • Mahalingam S. Sundaram,
  • Siddaiah Chandra Nayaka,
  • Kesturu S. Girish,
  • Arunachalam Chinnathambi,
  • M. E. Zayed,
  • Sulaiman Ali Alharbi,
  • Gautam Sethi,
  • Basappa,
  • Kanchugarakoppal S. Rangappa

Fig 2 appears incorrectly in the published article. Please see the correct Fig 2 and its caption here.

thumbnail
Download:
Fig 1. HCT116 cells were treated with different doses of API (0.5, 1, 5, and 10 μM) for 48 h, harvested and stained with propidium iodide and subjected to flow cytometry.

Histogram obtained indicated the accumulation cells in sub-G1 phase.

https://doi.org/10.1371/journal.pone.0175659.g001

Reference

  1. 1. Nirvanappa AC, Mohan CD, Rangappa S, Ananda H, Sukhorukov AY, Shanmugam MK, et al. (2016) Novel Synthetic Oxazines Target NF-κB in Colon Cancer In Vitro and Inflammatory Bowel Disease In Vivo. PLoS ONE 11(9): e0163209. pmid:27685808

Citation: Nirvanappa AC, Mohan CD, Rangappa S, Ananda H, Sukhorukov AY, Shanmugam MK, et al. (2017) Correction: Novel Synthetic Oxazines Target NF-κB in Colon Cancer In Vitro and Inflammatory Bowel Disease In Vivo. PLoS ONE 12(4): e0175659. https://doi.org/10.1371/journal.pone.0175659

Published: April 6, 2017

Copyright: © 2017 Nirvanappa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.